Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$70,000.00
Allosteric modulation of dopamine D2 receptor by PAOPA: Implications in the treatment of schizophrenia
FY 2010-11
Summary
Schizophrenia is a debilitating mental disorder that affects 1% of the world's population. It results from increased dopamine levels and D2 receptor activity. Dopamine is a chemical found in the brain known to regulate mood, attention, and other functions. In order to exert its effects in the body, it specifically binds and interacts with the dopamine receptor, including the D2 subtype. Current treatments for schizophrenia block the dopamine D2 receptor by binding to the same site as dopamine. However, these treatments are highly inadequate as they alleviate only some of the symptoms of schizophrenia while causing an array of adverse side effects, including weight gain, diabetes, and movement disorders. As a result, there is a high demand for a new generation of drugs that are safe and effective in treating schizophrenia. Our lab has developed a new compound, PAOPA, which uniquely interacts with an alternative site on the D2 receptor than the currently available drugs. PAOPA has shown effectiveness in the safe treatment of schizophrenic-like symptoms in one particular animal model of schizophrenia. This proposed study will further confirm the therapeutic effect of PAOPA in another animal model of schizophrenia, to gather conclusive evidence prior to moving this drug to human clinical trials. Additionally, past studies have shown that PAOPA increases the response of dopamine receptors to dopamine within the brain. Thus, in this study, we propose to prove that the mechanism by which PAOPA is therapeutic is that it by increasing dopamine binding, it results in a downregulation of dopamine receptors as they get internalized within the expressed cell. Thus, PAOPA leads to an overall decrease in dopamine signaling, resulting in decreased symptoms of schizophrenia. In summary, PAOPA can be developed into a new, highly effective class of antipsychotics with minimal adverse effects that can have a positive effect on all those suffering from schizophrenia.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
229625
Name
Basu Dipannita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Allosteric modulation of dopamine D2 receptor by PAOPA: Implications in the treatment of schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Allosteric Modulation; Antipsychotic Drugs; Dopamine D2 Receptor; Neonatal Hippocampus Lesion Model; Receptor Internalization; Schizophrenia
Abstract
Schizophrenia is a debilitating mental disorder that affects 1% of the world's population. It results from increased dopamine levels and D2 receptor activity. Dopamine is a chemical found in the brain known to regulate mood, attention, and other functions. In order to exert its effects in the body, it specifically binds and interacts with the dopamine receptor, including the D2 subtype. Current treatments for schizophrenia block the dopamine D2 receptor by binding to the same site as dopamine. However, these treatments are highly inadequate as they alleviate only some of the symptoms of schizophrenia while causing an array of adverse side effects, including weight gain, diabetes, and movement disorders. As a result, there is a high demand for a new generation of drugs that are safe and effective in treating schizophrenia. Our lab has developed a new compound, PAOPA, which uniquely interacts with an alternative site on the D2 receptor than the currently available drugs. PAOPA has shown effectiveness in the safe treatment of schizophrenic-like symptoms in one particular animal model of schizophrenia. This proposed study will further confirm the therapeutic effect of PAOPA in another animal model of schizophrenia, to gather conclusive evidence prior to moving this drug to human clinical trials. Additionally, past studies have shown that PAOPA increases the response of dopamine receptors to dopamine within the brain. Thus, in this study, we propose to prove that the mechanism by which PAOPA is therapeutic is that it by increasing dopamine binding, it results in a downregulation of dopamine receptors as they get internalized within the expressed cell. Thus, PAOPA leads to an overall decrease in dopamine signaling, resulting in decreased symptoms of schizophrenia. In summary, PAOPA can be developed into a new, highly effective class of antipsychotics with minimal adverse effects that can have a positive effect on all those suffering from schizophrenia.
Competitiondate
201010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Basu, Dipannita
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $70,000~ $0~